The IlluminOss system provides a simple, percutaneous surgical approach which enables surgeons to create a first-of-its-kind patient-conforming implant providing almost instant internal support of fractured bones, even those affected by cancer. Benefits observed often include smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.
IlluminOss has recently entered in to an agreement with Germany-based Orthovative to distribute the IlluminOss System in Germany. Founded in 2011 and headquartered in Tegernsee, Orthovative specializes in the distribution of innovative spine and orthopedic technology.
"We are extremely excited to be representing IlluminOss in Germany," said Rob Martin, Orthovative president and CEO. "This revolutionary technology adds a new tool for the surgeon when dealing with complicated and difficult fracture indications. Orthovative leads in Germany as a company dedicated to bringing the most innovative products to our customers and IlluminOss is a perfect fit for us. We look forward to working together and advancing orthopedics."
"Orthovative has an excellent reputation nationally and has the orthopedic market knowledge and connections to help us increase adoption of the IlluminOss System in Germany," said Manny Avila, CEO, IlluminOss. "Our technology provides surgeons with an entirely new and less invasive way to approach complex fracture repair and we are eager to make our system more accessible around the world and to keep up with growing demand via partnerships with esteemed distributors such as Orthovative."
The IlluminOss System has been used in the treatment of over a thousand patients in Europe, where it is commercially available and has been in clinical use since 2010. The company's technology is commercially available in Europe and it is currently executing on its first U.S. trial towards FDA approval.
DKOU 2015 will take place in Messe Berlin / Suedgelaende from October 20-23, 2015.
IlluminOss Medical is a privately held, commercial-stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through patient-specific intramedullary implants. The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach, providing patients and clinicians with a fast, patient-specific method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks.
The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.